Read more about the article Endometrial Cancer – Vistusertib Plus Arimidex in Patients With HR+
סרטן רחם - ארימידקס פלוס ויסטוסרטיב במטופלות עם HR+

Endometrial Cancer – Vistusertib Plus Arimidex in Patients With HR+

Importance Endometrial cancer is often hormone-dependent and treated with aromatase inhibitors, (AIs). The uncontrolled PI3K-AKT-mTOR pathway observed in this type of cancer drives hormonal resistance. Therefore, there is rationale of…

Continue ReadingEndometrial Cancer – Vistusertib Plus Arimidex in Patients With HR+